Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.43B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $29.3M in total
- 8
- 13F holdersQ2 2026, +30 vs. previous quarter
- 269
- 13F valueReported value at the end of Q2 2026
- $6.43B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DNTH, Q2 2026
No superinvestor reported holding DNTH at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Dianthus Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:36 PM ET | Sep 17 | 1 day | Carr EdwardCHIEF ACCOUNTING OFFICER | SSale | −20.0K | $101.38 | −$2.03M | −100.0%0 after | 5 lots10b5-1 |
| Sep 3, 2026 (view filing)4:30 PM ET | Sep 1 | 2 days | Randhawa SimratEVP, Head of R&D | SSale | −23.1K | $106.41 | −$2.46M | −85.3%4.00K after | 3 lots10b5-1 |
| Aug 19, 2026 (view filing)6:02 PM ET | Aug 19 | Same day | Read SimonDirector | SSale | −2.78K | $117.55 | −$326.6K | −100.0%0 after | 10b5-1 |
| Aug 11, 2026 (view filing)5:15 PM ET | Aug 10 | 1 day | McGeorge AnneDirector | SSale | −7.75K | $109.01 | −$844.8K | −100.0%0 after | 5 lots10b5-1 |
| Aug 11, 2026 (view filing)5:10 PM ET | Aug 10 | 1 day | Read SimonDirector | SSale | −2.78K | $109.55 | −$304.2K | −100.0%0 after | 6 lots10b5-1 |
| Aug 11, 2026 (view filing)5:08 PM ET | Aug 7-10 | 4 days | Veness Adam MSVP, General Counsel and Sec. | SSale | −20.0K | $110.44 | −$2.21M | −100.0%0 after | 3 lots10b5-1 |
| Aug 7, 2026 (view filing)6:30 PM ET | Aug 7 | Same day | Garcia MarinoCEO AND PRESIDENT | SSale | −166.0K | $108.11 | −$17.9M | −71.8%65.3K after | 7 lots10b5-1 |
| Jul 13, 2026 (view filing)5:00 PM ET | Jul 9 | 4 days | Savitz RyanEVP, CFO & CBO | SSale | −31.2K | $101.03 | −$3.16M | −100.0%0 after | 3 lots10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Veness Adam MSVP, General Counsel and Sec. | SSale | −30.0K | $80.80 | −$2.42M | −100.0%0 after | 2 lots10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Randhawa SimratEVP, Head of R&D | SSale | −26.5K | $90.62 | −$2.40M | −86.9%4.00K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Dianthus Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 8,199,893 | $799.3M | 0.03% | +432,207+5.6% | Added |
| BlackRock, Inc. | 4,123,822 | $402.0M | 0.01% | +948,119+29.9% | Added |
| T. Rowe Price Investment Management, Inc. | 3,888,456 | $379.0M | 0.25% | +2,596,274+200.9% | Added |
| Wellington Management Group LLP | 3,229,882 | $314.8M | 0.05% | +634,099+24.4% | Added |
| Fairmount Funds Management LLC | 2,537,191 | $247.3M | 16.35% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 2,514,946 | $245.2M | 0.02% | +1,367,998+119.3% | Added |
| State Street Corp | 2,357,440 | $229.8M | 0.01% | +958,527+68.5% | Added |
| Vanguard Capital Management LLC | 2,159,568 | $210.5M | 0.00% | +128,319+6.3% | Added |
| Avidity Partners Management LP | 2,104,184 | $205.1M | 32.85% | −2,104,184−50.0% | Reduced |
| Octagon Capital Advisors LP | 1,841,667 | $179.5M | 16.48% | −105,000−5.4% | Reduced |